ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
Pt(NH3)2Cl2
CAS番号:
分子量:
300.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
製品名
trans-白金(II)ジアンミンジクロリド, United States Pharmacopeia (USP) Reference Standard
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
SMILES string
N.N.Cl[Pt]Cl
InChI key
LXZZYRPGZAFOLE-UHFFFAOYSA-L
grade
pharmaceutical primary standard
API family
cisplatin
manufacturer/tradename
USP
mp
340 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1
保管分類
13 - Non Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Xi-Chun Hu et al.
The Lancet. Oncology, 16(4), 436-446 (2015-03-22)
Platinum chemotherapy has a role in the treatment of metastatic triple-negative breast cancer but its full potential has probably not yet been reached. We assessed whether a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabine
Koichi Azuma et al.
Oncotarget, 5(15), 5908-5919 (2014-08-15)
Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to
Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）